Business Wire

International Money Transfers at Your Fingertips With the DNBCnet App

Share

Sending money abroad has traditionally been an arduous and expensive task that frustrates users. Plus with the post-pandemic changes, people now need a faster yet cheaper contactless money transfer solution that can be done quickly on a mobile. That leads to the demand for payment apps.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005433/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

International money transfers at your fingertips with the DNBCnet app

But which ones are the best international payment apps? That depends. The best payment apps are the ones that work best for your business.

DNBCnet App - Powered by the leading Digital Banking Firm DNBC

Digital banking firm DNBC was founded by Le Hung Anh in 2017, professionally known as Jimmy Lee, headquartered in Singapore.

With the mission to support enterprises as well as individuals in financial transactions over the world, DNBC has developed the DNBCnet app in order to make the banking process easier yet cheaper by adapting more innovative changes right on the app.

“DNBCnet is an all-in-one tool for any user who wants to conduct international transactions, manage and control the cash flow of their business,” said Jimmy Lee, Founder & CEO of DNBC.

DNBCnet App offers exceptional benefits

Best for corporate international money transfers

When it comes to international payments, companies just want to make quick transactions while keeping the costs as low as possible.

It can be difficult to find a provider that offers quick transfers and low fees. But if you want to keep your business straightforward, you don’t have to look very far because DNBC business accounts will fit the bill.

“If you structure payments properly, digital banking can create more predictable cash flow over the life of your business,” said CEO Jimmy Lee.

Fastest ways to send money abroad

When sending money globally, an important factor besides fees is the speed. Speedy transfer will accelerate the business, otherwise it will slow down the whole operation significantly.

With DNBCnet app, recipients will get the fund instantly if transferred in DNBC network. It only takes 1-2 business days to send to someone outside the system.

Ease of use

DNBCnet works as a mobile app, the signing up process can be done quickly with a few simple steps. It owns a seamless visual interface which allows users to handle payments in no time.

On top of that, you can keep track of your transfer and get updates along the way, so you’re always in the loop about your funds.

Utmost safety for mobile banking

Security is a must for any financial app. DNBC has raised its standard by adopting the latest technology such as two-factor authentication, data encryption for every transaction.

That will help protect account information and transactions to the fullest extent preventing any potential frauds for customers and businesses.

As a bonus perk

Besides the core function, DNBCnet also adds up a number of accompanying features to make it even more favorable. Users now can also check real-time exchange rate information, view financial statistics by charts, send mobile top up and many more.

Level up your payment practice with DNBCnet app

One of the key benefits of digital banking apps is that they allow users to manage payments anywhere and anytime. With that, business owners can focus on delivering services, not bothering with the payment process.

DNBCnet app offers exceptional convenience and transparency to its users. Via smartphones, you can find the IOS version for mobile banking on the App Store or mobile banking app for Android in the Google Store. Or simply search for DNBCnet.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Name: Oliver Nguyen
Title: Vice Director
Email: oliver.ng@dnbcf.com
Phone: +370 5240 5555

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye